| Factor Information | |
|---|---|
| Data ID | 4175 |
| Factor | mortality at 10 years stratified by age under and over 35 at pulmonary valve replacement(expected) |
| Description | Patients aged 35–50 undergoing pulmonary valve replcement had a higher risk of death at 10 years than that of the matched general population, compared to those undergoing pulmonary valve replcement before 35 years (HR 9.9 vs 7.4). |
| Biomarker | NA |
| Classification | A3 (clinical factor - disease & symptom) |
| Association | |
|---|---|
| Application | risk assessment |
| Objective | To evaluate the impact of age at PVR(pulmonary valve replacement) on outcomes |
| p Value | <0.001 |
| Conclusion | Patients aged 35–50 undergoing pulmonary valve replcement had a higher risk of death at 10 years than that of the matched general population, compared to those undergoing pulmonary valve replcement before 35 years (HR 9.9 vs 7.4) and a higher mortality excess of 7.7% (3.2–15.3%) versus 0.9% (0.2–2.6%). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 53 |
| CHD Type | isolated CHD |
| CHD Subtype | TOF |
| Reference | |
|---|---|
| PMID | 32187367 |
| Year | 2020 |
| Title | Age over 35 years is associated with increased mortality after pulmonary valve replacement in repaired tetralogy of Fallot: results from the UK National Congenital Heart Disease Audit database |
| Sample | ||
|---|---|---|
| Population | adolecents, adults | |
| Source | patients | |
| Region | London, UK | |
| Method | Kaplan–Meier analysis | |
| Race | European | |
| Disease History | with 5.1% genetic conditions | |
| Treatment History | pulmonary valve replacement | |
| Group | >35 years(Treatment) | < 35 years(Control) |
| Number | 211 | 495 |
| Age | >35 years | < 35 years |
| Gender (Male: Female) | 385:321 | 385:321 |
| Marker Level | estimated: 2.7% (2.6-2.8%); hazard ratio:9.9 | estimated: 0.4% (0.38-0.43%); hazard ratio:7.4 |
